<DOC>
	<DOCNO>NCT01692262</DOCNO>
	<brief_summary>To investigate safety , tolerability anti-tumour activity AZD5363 , monotherapy , patient metastatic Castrate-Resistant Prostate Cancer . AZD5363 investigate patient progress chemotherapy ( Part A ) patient progress receive chemotherapy ( Part B ) . Recruitment Part A , Group 1 suspend . A new design group currently evaluate . Part A , group 2 patient ( progress 1 2nd generational anti-hormonal therapy ) receive AZD5363 480mg bid intermittently ( 4 day on/3days ) . Part B start evidence anti-tumour activity along AZD5363 acceptable safety profile Part A . Part B conduct pre-chemotherapy patient dose schedule select Part A .</brief_summary>
	<brief_title>Investigating Safety , Tolerability Efficacy AZD5363 Prostate Cancer .</brief_title>
	<detailed_description>A Phase Ib Multicentre Study AZD5363 Monotherapy Assess Anti-Tumour Activity , Safety , Tolerability , Pharmacokinetics Patients With Metastatic Castrate-Resistant Prostate Cancer ( mCRPC ) ( PYRUS )</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Provision inform consent Males age 18 year old Histologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell feature standard therapy currently consider appropriate Documented evidence Metastatic CastrateResistant Prostate Cancer ( mCRPC ) Part A : Patients must receive prior docetaxelbased chemotherapy mCRPC Circulating Tumour Cell score 5 ; Part B : Patients must progress receive chemotherapy mCRPC ; Any prior exposure agent inhibit AKT primary pharmacological activity Any evidence severe uncontrolled systemic disease , include uncontrolled hypertension , active bleeding diatheses , active infection include hepatitis B , hepatitis C , human immunodeficiency virus Spinal cord compression brain metastasis unless asymptomatic , treated , stable require steroid Clinically significant abnormality glucose metabolism Major surgery within previous 4 week</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Metastatic Castrate-Resistant Prostate Cancer ( mCRPC ) ,</keyword>
	<keyword>adenocarcinoma prostate ,</keyword>
	<keyword>prostate cancer ,</keyword>
	<keyword>progressive disease ,</keyword>
	<keyword>advanced disease .</keyword>
</DOC>